TEAEs of grade 3 or higher in 5% or more of patients
| Preferred term . | CHAM (n = 96) . | Control (n = 97) . | P value (Fisher exact test) . |
|---|---|---|---|
| Febrile neutropenia | 32.3% | 32% | >.9999 |
| Anemia | 29.2% | 32% | .7573 |
| Thrombocytopenia | 17.7% | 13.4% | .4336 |
| White blood cell count decreased | 15.6% | 13.4% | .6877 |
| Neutrophil count decreased | 12.5% | 14.4% | .8335 |
| Lymphocyte count decreased | 11.5% | 11.3% | >.9999 |
| Sepsis | 10.4% | 10.3% | >.9999 |
| Hypokalemia | 6.3% | 9.3% | .5923 |
| Pneumonia | 6.3% | 8.2% | .7826 |
| Neutropenia | 7.3% | 1% | .0348 |
| Acute kidney injury | 6.3% | 0% | .0140 |
| Tumor lysis syndrome | 0% | 6% | .0289 |
| Preferred term . | CHAM (n = 96) . | Control (n = 97) . | P value (Fisher exact test) . |
|---|---|---|---|
| Febrile neutropenia | 32.3% | 32% | >.9999 |
| Anemia | 29.2% | 32% | .7573 |
| Thrombocytopenia | 17.7% | 13.4% | .4336 |
| White blood cell count decreased | 15.6% | 13.4% | .6877 |
| Neutrophil count decreased | 12.5% | 14.4% | .8335 |
| Lymphocyte count decreased | 11.5% | 11.3% | >.9999 |
| Sepsis | 10.4% | 10.3% | >.9999 |
| Hypokalemia | 6.3% | 9.3% | .5923 |
| Pneumonia | 6.3% | 8.2% | .7826 |
| Neutropenia | 7.3% | 1% | .0348 |
| Acute kidney injury | 6.3% | 0% | .0140 |
| Tumor lysis syndrome | 0% | 6% | .0289 |
TEAEs were defined as adverse events occurring on or after the first dose of study drug and including 30 days past end of study treatment. TEAEs are coded using MedDRA (version 24.0). Bold values indicate statistical significance.